Reported 2 days ago
Recursion Pharmaceuticals offers an exciting opportunity in the biotech sector, leveraging AI for drug discovery, but it has yet to launch a product and faces a volatile stock price after a significant decline. Investors should note its promising candidate pipeline, including potential treatments for rare diseases, alongside its limited financial performance, which shows a need for market approval to improve its position. With several critical milestones approaching in 2025, Recursion remains a risk that may be worth keeping an eye on, but until it proves its viability, cautious investors might consider waiting.
Source: YAHOO